Beam Therapeutics Inc. entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. on February 9, 2026, to ensure continued access to certain patents if the existing license between Kobe and Bio Palette terminates, with financial consideration payable directly to Kobe after such termination.
Key takeaways
Beam Therapeutics entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. on February 9, 2026.
The agreement grants Beam an exclusive license to practice certain patents if the Kobe-Bio Palette License terminates, excluding specific termination scenarios.
Financial consideration involves Beam paying Kobe amounts that would have been payable to Bio Palette under Section 4.4 of the Bio Palette-Beam License after termination.
Beam assumes responsibility for patent prosecution and maintenance costs for the Kobe Patents after the effective time of termination.
The agreement is governed by New York law and includes dispute resolution provisions referencing the License Agreement.
Kobe must send Beam a copy of any termination notice sent to Bio Palette regarding the Prime License.